| Name | Title | Contact Details |
|---|
We are The Stem Cell Nutrition Company®, pioneers in stem cell science, and we have demonstrated that adult stem cells function as the natural renewal system of the body. Our products enhance and support the work of the body`s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our Mission is to enhance wellness and prosperity around the world. The company expands to over 30 countries!
Women's Health Initiative is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Definity Health is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ABC Medical Billing Consultants is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.